



KILPEST INDIA LIMITED

 REGD. OFFICE & FACTORY :

 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 INDIA

 Tel
 91-755 2586536, 2586537
 FAX NO. : 91-755 2580438

 E-mail : kilpest@bsnl.in kilpestbpl@yahoo.co.in
 Visit us at : www.kilpest.com

 CIN : L24211MP1972PLC001131

June 23, 2021

The Relationship Manager, Department of Corporate Relations Bombay Stock Exchange Ltd (BSE), P.J. Towers, Dalal Street Fort, MUMBAI – 400 001

Dear Sir/Madam,

Please find the enclosed herewith Investor's Presentation / Company Update of Agrochemicals and Diagnostic Kits (Health Care) for your information and necessary

action.

Thanking you, Yours faithfully, For KILPEST INDIA LTD,

LIN

Nikhil Kuber Dubey Whole Time Director DIN: 00538049

Encl: a/a











Farmer's Trusted Agro-Input Partner for 49 Years

Reliable and Affordable Healthcare Diagnostic Solutions

INVESTOR PRESENTATION

June' 2021





Safe Harbour

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.





We are together

Dear Shareholders,

Before we start with the review of the financial and business results of the fiscal year 2020-21, I would like to take a moment to express my condolences and pay my respects to all our employees, shareholders, suppliers and customers who have suffered loss of family members, friends, colleagues or loved ones due to the Coronavirus, which cannot be accounted for and is immeasurable in all terms. This pandemic has taken a gigantic toll on the mankind around the world. We are all together in this hour of grief. Let us all honour and cherish the memories of the people who have left us too soon and keep them alive in the works we do ahead.




Year 2020 and 2021 made its mark in the timelines of millions. It has brought big changes in people's life and society. I am proud to announce that Year 2020-21 has unveiled the never ending commitment and dedication to bringing a change in the people's life by providing world-class and affordable agro and healthcare solutions.


FINANCIAL PERFORMANCE AND KEY HIGHLIGHTS





Performance Highlights – Q4 & Full Year





KILPEST (Consolidated)	Q4 F21	Q4 FY20	FY21
Net sales	1888.16	674.07	22674.18
Profit before tax	954.45	311.94	15203.59
Profit after tax	710.04	227.93	11386.90
Paid up Equity share capital	750.81	750.81	750.81
Reserves	2462.10	1636.39	2462.10
Earnings Per Share (Rs.)	9.47	3.02	151.68

KILPEST (Standalone)	Q4 F21	Q4 FY20	FY21
Net sales	386.77	239.34	1435.69
Profit before tax	-26.73	11.23	208.41
Profit after tax	-23.40	11.23	171.83
Paid up Equity share capital	750.81	750.81	750.81
Reserves	1329.16	495.09	1329.16
Earnings Per Share (Rs.)	-0.31	0.15	2.29

Rs. In Lakhs





Key Highlights - Agrochemicals

Impact of COVID-19

- □ There was a potential loss in the production/sales during the first quarter of FY21.
- The sales for the year remain static for agrochemicals due to nationwide lockdown and events related to COVID-19.
- □ Company continues to focus on Public Health/Warehousing sector and Exports. As due to COVID-19, Private agriculture market is uncertain, and management doesn't want to increase financial exposure due to uncertainty.

Main Thrust Area of R&D

- Development of novel formulations for agriculture and public health which are less harmful and cost effective.
- □ Performance monitoring of existing products/process.
- □ Improvement in existing products/process with a customer driven approach.

Reduction in Debt

As proposed earlier, we are proud to confirm that our bank borrowing is below INR 1CR.





Kilpest Existing Products

Chemicals		Bi	Biologicals		
	No. of Products		No. of Products		
Insecticides	70	Bio pesticide	07		
Antibacterials	01	Bio fungicide	01		
• Fungicides	15	Bio fertilizers	05		
Herbicides	11	Bio nematicides	01		
Public Health	11	Public Health	02		
Microfertilizers	02	Health & Hygiene	06		
Chelated Zinc	01	Repellents	03		
Plant Growth Regulators	02				

Company to increase its focus on brand building on Micro fertilizers / Bio fertilizers and Public Health Products.



From the house of **KILPEST INDIA LTD.**

Kilpest India Limited,

India's most trusted agro-chemical brand proudly brings



First licensed Molecular Diagnostics (IVD) manufacturing facility in India under Medical Device Rule 2017

INFECTIOUS DISEASES

WOMEN'S HEALTH

PUBLIC HEALTH





Introduction – 3B BlackBio Biotech India Limited

"3B BlackBio Biotech India Limited", a subsidiary of Kilpest India Limited, embarked on its mission in 2011 with a vision to provide reliable, accurate and affordable healthcare solutions to all. Ever since its inception, 3B BlackBio is engaged in **Design, Development, Manufacturing and Commercialization of qPCR & NGS based Molecular Diagnostic Kits** for reliable testing of patient samples for infectious disease to various terminal diseases like Cancer. We are an **ISO13485:2016 certified**, **GMP Compliant Biotech R&D Organization**. Our PCR based Molecular Diagnostic Kits are manufactured by our parent company "Kilpest India Limited" and are commercialized with **"TRUPCR®"** brand of "3B BlackBio Biotech India Limited" to renowned diagnostics labs across India and many prestigious customers globally.

We are the **1st Indian molecular diagnostics company** to have in-house R&D for qPCR & NGS test development. With over a decade of experience in R&D and commercialization of molecular testing kits for human diagnosis, we have developed **more than 100 tests** and many more are in the pipeline. Our kits are being manufactured in our state of the art manufacturing facility located in Bhopal, India. Being an import substitution product it has helped the country to save precious foreign exchange. Since our products have been validated to international standards & reference material, we help build confidence in the medical fraternity for **"Make in India"** products.

We happily announce ourselves as the proud recipient of the prestigious "National MSME Award – 2018" by the Honourable President of India, Shri Ram Nath Kovind for our "TRUPCR® BCR ABL1 Quantitative Kit" for detection of BCR-ABL1 fusion gene in patients suffering with Chronic Myeloid Leukaemia (CML) & monitor response to drug therapy, on WHO international standards.

We were the 2nd Indian Company to develop the Real-Time PCR Test Kit for detection of SARS-CoV-2 and it has been commercialized under the name "TRUPCR® SARS-CoV-2 RT qPCR Kit". We proudly announce ourselves as the 1st company in India to get the USFDA approval for our "TRUPCR® SARS-CoV-2 RT qPCR Kit" and it has been EUA approved by USFDA for testing on saliva specimens as well.

TRURAPID® and TRUNGS® are also registered as the brand names of "3B BlackBio Biotech India Limited".





TRUPCR® from 3B BlackBio Biotech (I) Ltd.



Our Vision:

To offer reliable, affordable and effective healthcare solutions to all by recognizing the great potential of biotechnology to effectively diagnose rare, chronic and severe illnesses.




Our Mission:

To design and develop molecular diagnostics products of superior quality and value that continuously improves the patient's life. To become a global organization and to be recognized through quality; innovation and competence.





Timeline & Milestones








Growth Canvas









Financial Highlights – FY 2020 - 21







Rs. In Lakhs.





Events related to COVID -19

In the beginning of March, when India started reporting increasing cases of this new virus COVID-19 and we got ourselves into developing the RT-PCR based kit for its testing which was declared by WHO as the gold standard technique to test patient samples for the presence of Virus.

- We got the approval from ICMR on 2nd April, 2020 and license from CDSCO on 4th April, 2020 for selling RT-PCR Kit for COVID-19, under its brand name TRUPCR® SARS-CoV-2 RT qPCR Kit (Real-Time PCR based detection of SARS-CoV-2 virus) Version 2.0 with a sensitivity and specificity of 100% for detection of SARS-CoV-2. We were the only Second company to get the ICMR approval of our RT-PCR Kit. The company also launched in June 2020, its single tube multiplex assay for TRUPCR® SARS-CoV-2 RT qPCR Kit (Real-Time PCR based detection of SARS-CoV-2 virus) Version 3.2.
- Shortly after the approvals, demand skyrocketed and from the production capacity of 5,000 tests a day, we started scaling up our efforts to produce more than 100,000 tests per day.
- □ It was June 2020, when we became FIRST EVER Indian molecular diagnostics company to receive US-FDA EUA (Emergency Use Authorization) to make our mark on the global IVD industry. We further also received EUA on our RT-PCR kit for Saliva samples. With that, we became the 5th company in the world to offer US-FDA approved solution for saliva sample testing for patients.
- Even with the tough competition, the company was able to sell over 7 million tests by the end of FY 2020-21, and in April-May 21, we sold close to 3 million tests taking our total figure to over 10 Million which is a big milestone and a matter of pride for the company as we were able to serve the nation in this situation of pandemic. We are proud to say that our tests have saved millions of lives and supported the country to take a step forward towards being self-dependent in healthcare services.
- In April 2021, TRUPCR® SARS-CoV-2 RT qPCR Kits were added to the FIND Test Directory. FIND Test Directory is a global directory of all the tests available for COVID-19 diagnosis and is supported by the WHO, the European Commission, France, and the Bill & Melinda Gates Foundation.
- □ For a company of our size, I am proud to say that we have been on a success path from having a modest beginning to becoming a world-class manufacturing enterprise with global quality certifications for our products.
- Despite severe competition and numerous suppliers, still we are trying to maintain our position in the market, and we are one of the most preferred brands having largest customer base in the country.



INFECTIOUS DISEASES

ONCOLOGY



HUMAN GENETICS

Business Outlook – Post COVID

Due to COVID-19, nationally and internationally, number of Molecular Diagnostics Labs and manufacturers have increased manifolds, but with COVID-19 infections potentially decreasing now after June 2021, lot of labs might shut down due to non-viability, still there would be substantially more labs than in 2019. Although we already have more than 400 customers, we would be aggressively pitching to add new customers. We aspire to offer reliable & better customer experience and support to gain the edge over our competitors.

Although COVID-19 cases are coming down and lockdown being opened, however, the non-COVID diagnostics sales has still not picked up as there is a limited movement of patients for other diagnosis due to COVID-19 restrictions. We hope with the lockdown easing, the non-COVID business should start picking up July onwards.

Utilization of Funds

We are looking for options to acquire a company in similar business area to get inorganic growth in FY22 and onwards. We will only go for the acquisition if it makes financial sense and meets our internal IRR criteria. We would also be looking at share buyback in FY22/23 if we are unable to secure a desired acquisition candidate. Our aim is to create maximum value for our shareholders.

WOMEN'S HEALTH

PUBLIC HEALTH





HUMAN GENETICS

Scheme of Amalgamation

The Scheme of Amalgamation has been duly vetted by BSE on 31st May 2021, and the same is uploaded on the website of BSE. With SEBI approval and thereafter filing with NCLT and its approval, the Scheme of Amalgamation would come in force. Your company is working on faster approval of the scheme, which should result into unlocking the value of Material Subsidiary i.e. 3B BlackBio Biotech India Ltd.

Dividend Payment

Board is pleased to recommend a final dividend of Re.1/- i.e. @ 10% for the Financial Year 2020-21. Also, a special interim dividend of Rs. 8/- i.e. 80% per share is being declared for the Financial Year 2021-22, thus taking a total dividend payout of Rs. 9/- per share.

Proposed Listing on National Stock Exchange (NSE)

The most widely accepted objective of the Company is to maximize the value and wealth of its shareholders. Keeping this objective in mind, Company has already initiated the scheme of arrangement/merger to unlock the value of its Material Subsidiary i.e. 3B BlackBio Biotech India Ltd. Post completion of the said scheme of arrangement/merger, company would initiate the listing of its shares on the National Stock Exchange (NSE) also.

WOMEN'S HEALTH

PUBLIC HEALTH

INFECTIOUS DISEASES

ONCOLOGY



ONCOLOGY

INFECTIOUS DISEASES



HUMAN GENETICS

R&D Strategy & Rapid Antigen Business Vertical

Company's continuous focus on the Research and development (R&D) activities is a valuable tool for growing and improving business. R&D involves researching, developing new and improved products, business verticals, and processes and services to fit the basic needs of society. Company strongly believes that businesses that have an R&D strategy have a greater chance of success than businesses that do not. Company is in the advanced stage of developing Rapid Antigen Business Vertical (Rapid Test Kits) for Covid19 and other parameters.

Expansion and Additional Capacity

Company is continuously investing in building up additional manufacturing and R&D facilities / capacities to cater to the existing business verticals. Further, company is also building a new manufacturing facility for proposed Rapid Antigen Tests.

Next-Gen Sequencing (NGS) Vertical

NGS is a new technology used for DNA and RNA sequencing and variant/mutation detection. NGS can sequence hundreds and thousands of genes or whole genome in a short period of time. Your company is working on the commercial launch of the same, however, due to COVID-19 Pandemic Situation, the work had slowed down. Now the development work has been restarted and company expects to launch NGS assays in next 2 -3 quarters.

WOMEN'S HEALTH

PUBLIC HEALTH





Exports

In 2019-20 our exports were INR 6.55 million yearly and in Year 2020-21, it increased substantially to INR 19.78 million. This year we want to focus on exports, although our products have been well-accepted in more than 15 countries but due to restriction on exports of RT-PCR Kits we have to slow our marketing strategy, as we can't take new orders without a clear picture on new licensing window or removal of restrictions. We are pursuing with government to remove restrictions and hope that July onwards situation will change.







Strong Brand Presence


□ We have grown ourselves to be a strong brand in the Indian and Global Molecular Diagnostic Market

□ With our in depth knowledge of research products, we continuously add new products to our portfolio

□ On field demonstration of products, training of end-users to use the products, building awareness among stakeholders in relation to the products

□ Pan India Distribution network that ensures strong presence in all states of India

□ Scale and diversity of product offerings lead to us being the preferred molecular diagnostic supplier for our customers









R & D



•Highly educated team of scientist from varied backgrounds

•Dedicated teams for respective segments

•Separate onco team headed by researchers (Ph.Ds.) from oncology background

•Separate team for infectious parameters headed by researchers (Ph.Ds.) from infectious diseases background

Laboratory Infrastructure

Separate R&D section

•BSL 2 extraction rooms

•Clean Rooms (ISO-7 / Class 10,000 with double door entry) for assay preparations & downstream activities







Product QC - Our Strength



CE 🎯

All TRUPCR® products are passed through stringent QC protocols to ensure optimal performance at customer site

- QC of raw material
- QC of every final lot
- Cherrypicked QC of final batch

Besides above routine QC practices,

Kits are QC checked on respective* real-time cyclers

*We guarantee an unmatched performance of TRUPCR kits on any real- time PCR cyclers, which is the reason that the ordered product is QC check on the customer's real-time PCR brand and model






Our Certificates








Technology Focus







Product Segments








All Inclusive TRUPCR® Products

TRUPCR® range of products offers end-to-end standardized solutions from samples to optimized end-results



ONCOLOGY

INFECTIOUS DISEASES

WOMEN'S HEALTH

PUBLIC HEALTH

Π





Global Recognition

List of recommended BCR-ABL WHO IS tests

Only INDIAN company listed in global survey*

*Survey conducted by Diaceutics UK, Consultants to Novartis

Location of Company	Company	Sensitivity	Complete workflow solution available	Includes Reverse Transcriptase step design	Alignment with IS	Simultaneous step for Major and Minor transcript
France, Europe	Elitech - PCR alert kit	MR4.0	X	X	WHO	Х
INDIA	3B BlackBio - TRUPCR® BCR- ABL1 Kit	MR4.5	\checkmark	\checkmark	WHO	\checkmark
Italy, Europe	AB Analitica Real quality-RS-BCR- ABL p210	MR4.5-5.0	X	X	WHO	Х
Netherlands, Europe	QiagenIS MMR kit	MR4.0	\checkmark	X	WHO	Х
Netherlands, Europe	Qiagen BCR-ABL1 Mbcr RGQ RT-PCR Kit	MR4.5	\checkmark	\checkmark	WHO	Х
Singapore	VelaDx Sentosa® SA BCR-ABL Major Quantitative RT-PCR Test	MR4.5	\checkmark	√	WHO	Х
USA	Cepheid Gene Xpert	MR4.0	\checkmark	√	v1 –sample exchange v2- WHO	Х
USA	Cepheid Ultra	MR4.5	\checkmark	\checkmark	WHO	Х
USA	EntroGen BCR-ABL p210 (Mbcr) One-Step Detection Kit	MR5.0	X	√	WHO	Х
USA	Asuragen QuantideX BCR-ABL IS CMR	MR4.7	\checkmark	X	WHO	X
USA	MolecularMD BCR- ABL1IS MR3 AssayTM	MR3.0	X	X	WHO	Х

Π





Growth Drivers

	Improvement in Indian healthcare industry with high demand in medical tourism
External Growth Drivers	 Increasing number of molecular tests being introduced by labs
	• Evolution of disease profiles. New viruses and cancers are been diagnosed
	 Increase in evidence-based treatments / Drug response monitoring
	 Companion diagnostic assays, which aid in determining prognosis and drug response (pharmacogenomics)

	 India Specific tests with comprehensive validation on MULTIPLE gene pool
	 Unique designing strategy for each test to offer something extra for better actionable information
Internal Growth Drivers	 Compliance with international standards and guidelines
	Comprehensive coverage of genes/targets
	Positioned with cost advantage
	 Faster Turn-around time with unmatched customer support





National MSME Award- 2018 by Hon'ble President of India, Shri Ram Nath Kovind.







Hon'ble President of India, Shri Ram Nath Kovind on Friday on the occasion of 20th National Technology Day presented the national award for successful commercialization of indigenous technology at Vigyan Bhavan, New Delhi. 3B BlackBio Biotech India Limited, Bhopal (M.P.) (A subsidiary of Kilpest India Limited) have been declared as the winner of National Award 2018 under MSME category for the successful commercialization of a technology based product- "TRUPCR® BCR ABL1 Quantitative Kit" for detection of BCR-ABL1 fusion gene in patients suffering with chronic myeloid leukemia (CML) & monitor response to drug therapy, on WHO international standards.





Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal.





3B BLACKBIO BIOTECH (I) LTD. Bhopal is awarded with the 'Outstanding Achievement Award in recognition of excellence in R&D through technology in MSME enterprise category', during the 4th Outstanding Achievement Award 2016, held on 12th Aug. 2017 (Saturday), organized by Federation of Madhya Pradesh Chambers of Commerce and Industry (FMPCCI), Bhopal The award was received by Mr. Dhirendra Dubey (Managing Director), Mr. Nikhil Dubey (Director) & Dr. Akhilesh Rawat (Head R&D), from Hon'ble Chief Minister of M.P. Shri. Shivraj Singh Chouhan





JAI HIND

ONCOLOGY INFECTIOUS DISEASES WOMEN'S HEALTH PUBLIC HEALTH HUMAN GENETICS